{"schema_version":"secwatch.filing_event.v1","accession":"0000917520-26-000033","form_type":"8-K","ticker":"IART","cik":"0000917520","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","filed_at":"2026-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.932732+00:00","generated_at":"2026-05-14T23:44:05.892061+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Integra Q1 2026: Adj. EPS $0.54 vs $0.41; raises FY adj. EPS guidance to $2.40-$2.50","bullets":["Q1 revenue $391.9M (+2.4% reported; +1.3% organic). GAAP net loss $(4.6)M vs $(25.3)M prior year.","Adjusted EPS $0.54 vs $0.41; adjusted gross margin 64.1% vs 62.2%. Adjusted EBITDA $76.2M (19.4% rev).","Specialty Surgery rev $283.1M (+0.9% rep, -0.6% organic); Tissue Reconstruction $108.8M (+6.7% rep, +6.4% organic).","Reaffirms FY rev guidance $1.662B-$1.702B; raises adj. EPS guidance to $2.40-$2.50 from $2.30-$2.40.","Braintree facility on track to begin SurgiMend production by end of June for Q4 launch; PriMatrix/Durepair returning."],"urls":{"canonical":"https://secwatch.observer/filing/0000917520-26-000033","json":"https://secwatch.observer/filing/0000917520-26-000033.json","markdown":"https://secwatch.observer/filing/0000917520-26-000033.md","text":"https://secwatch.observer/filing/0000917520-26-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/917520/000091752026000033/0000917520-26-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/917520/000091752026000033/iart-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:44:05.892061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"812d4672560822128cb556f9da25f49ea881177c","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported the first quarter ending March 31, 2026 results: revenue $391.9 million, net income $(4.6) million, EPS $(0.06) per diluted share. Guidance raised.","evidence_excerpt":"Total reported revenues of $391.9 million increased 2.4% on a reported basis and 1.3% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 55.4%, compared to 50.8% in the first quarter of 2025. Adjusted gross margin was 64.1%, compared to 62.2% in the prior year. Adjusted EBITDA for the first quarter of 2026 was $76.2 million, or 19.4% of revenue, compared to $63.6 million, or 16.6% of revenue, in the prior year. The Company reported a GAAP net loss of $(4.6) million, or $(0.06) per diluted share, in the first quarter of 2026, compared to GAAP net loss of $(25.3) million, or $(0.33) per diluted share, in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752026000033/0000917520-26-000033-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ending March 31, 2026"},{"label":"Revenue","value":"$391.9 million"},{"label":"Net income","value":"$(4.6) million"},{"label":"EPS","value":"$(0.06) per diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}